Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Niacin and Substance P

supplement:

Niacin

Research Papers that Mention the Interaction

The rapidity and the degree of the changes in SPLI after nicotine exceed those previously reported for other agents and implicate substance P neurotransmission as a major component of nicotinic action.
Neurochemical Research  •  2004  |  View Paper
However, such treatment with SP enhanced nicotinic responses evoked by local pressure ejections of ACh (10 mM, 10- to 100-ms duration) in 77% of intracardiac neurons studied (n = 52).
American journal of physiology. Regulatory, integrative and comparative physiology  •  2001  |  View Paper
SP is known to have the following two effects on nicotine‐induced secretion of catecholamines (see Livett and Zhou, 1991): inhibition of the nicotinic response and protection against nicotinic desensitization.
Journal of neurochemistry  •  1994  |  View Paper
Although agonists specific for either nicotinic or muscarinic receptors stimulated release of NE, SP selectively inhibited the nicotinic component of transmitter secretion.
Journal of neurophysiology  •  1993  |  View Paper
6 At a higher concentration (10−5m), SP inhibited total nicotinic CA secretion throughout S1 and produced a biphasic secretion of CA (depressed in the presence of SP and enhanced after wash out of SP).
In addition to the ability of SP to increase or decrease the total amount of adrenal CA secretion, dependent on the concentration of SP, the present study shows that SP can change the time‐course of nicotinic CA secretion.
British journal of pharmacology  •  1991  |  View Paper
We suggest that SP protects some receptors from nicotinic desensitization while holding them in an inactive state, and that upon removal of SP these receptors can slowly respond to DMPP.
Journal of neurochemistry  •  1990  |  View Paper
Previous studies show that SP has an inhibitory effect on the nicotinic response in a number of different tissue preparations.
These results suggest that SP facilitates CA secretion from the adrenal gland at two levels: (1) pre‐synaptically by facilitating ACh release from splanchnic nerve terminals, and (2) post‐synaptically by modulating the nicotinic secretory response by protection against nicotinic desensitization of secretion.
The Journal of physiology  •  1990  |  View Paper
At low concentrations, up to 3 microM, SP partially inhibited or partially protected the nicotine response by 15-20%, and at high concentrations (30 microM), SP markedly inhibited or markedly protected the nicotinic response by 80 or 92%, respectively.
It is concluded that SP is more potent at protecting against desensitization than at inhibiting the nicotinic response and that SP might modulate CA release through activation of two receptor subtypes.
SP exhibited biphasic effects in its actions of inhibiting the nicotinic secretory response and protecting against desensitization.
Brain Research  •  1988  |  View Paper
The action of SP was significantly reduced by pretreatment with muscarinic and nicotinic cholinergic, dopamine and histamine (H1) receptor antagonists.
Neuropeptides  •  1987  |  View Paper
This suggests that the previously reported ability of SP to modulate nicotinic receptor function in vitro by either inhibiting the nicotinic response or protecting against nicotinic desensitization may be more than a mere pharmacological curiosity.(ABSTRACT TRUNCATED AT 400 WORDS)
The Journal of physiology  •  1986  |  View Paper
Show More